During the afternoon session, Amgen moved 1.79%, compared to -0.56% for the S&P 500.
Amgen Inc. (formerly Applied Molecular Genetics Inc. The company is now trading -11.18% away from its average analyst target price of $258.76 per share. The 21 analysts following the stock have set target prices ranging from $175.0 to $325.0, and on average give Amgen a rating of hold.
Over the last year, AMGN shares have gone up 2.65%, which represents a difference of 9.45% when compared to the S&P 500. The stock's 52 week high is $292.06 per share whereas its 52 week low is $219.83. With its operating margins declining an average -10.29% over the last four years, Amgen may not have a strong enough business to keep this trend.
| Date Reported | Revenue (k) | Cost of Revenue (k) | Gross Margin | YoY Growth |
|---|---|---|---|---|
| 2022-12-31 | $51,272,000 | $14,987,000 | 70.77% | -1.17% |
| 2021-12-31 | $50,799,000 | $14,422,000 | 71.61% | 0.69% |
| 2020-12-31 | $25,424,000 | $7,343,000 | 71.12% | -6.91% |
| 2019-12-31 | $23,362,000 | $5,514,000 | 76.4% | -1.57% |
| 2018-12-31 | $23,747,000 | $5,315,000 | 77.62% | n/a |
